Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 4,178 GBp
Change Today +29.00 / 0.70%
Volume 2.7M
As of 11:35 AM 07/7/15 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

Open
4,180 GBp
Previous Close
4,149 GBp
Day High
4,211 GBp
Day Low
4,167 GBp
52 Week High
04/23/15 - 4,906 GBp
52 Week Low
06/30/15 - 4,019 GBp
Market Cap
52.8B
Average Volume 10 Days
2.7M
EPS TTM
1.02 GBp
Shares Outstanding
1.3B
EX-Date
02/19/15
P/E TM
63.3x
Dividend
3.03 GBp
Dividend Yield
4.71%
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. In addition, it engages in the insurance and reinsurance underwriting business. The company has collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., and Pharmacyclics Inc. and Janssen Research & Development, LLC. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

57,500 Employees
Last Reported Date: 03/10/15
Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.1M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 1.7M GBP
Compensation as of Fiscal Year 2014.

astrazeneca plc (AZN) Key Developments

AstraZeneca and The University of Adelaide Announce Collaboration Set to Aid Drug Discovery

AstraZeneca and the University of Adelaide have announced an exciting new collaboration which will see 50 of AstraZeneca’s drug compounds passed to university researchers to study new therapies. return for first rights for AstraZeneca to commercialize any discovery that university researchers make, the university will have access to compounds in several therapy areas, such as cardiovascular, metabolic, respiratory, oncology, autoimmune and infection, and neuroscience diseases. The collaboration is based on AstraZeneca’s Open Innovation platform, which takes its new and existing drug compounds out of AstraZeneca’s laboratories and into the hands of research centres around the world. Adelaide Research and Innovation (ARI), the University of Adelaide’s commercialization arm, sealed the agreement which is a first for South Australia. AstraZeneca and ARI will also agree to fund successful research proposals that result from the partnership which have the potential to expand the reputation of the University of Adelaide and South Australia as a centre for medical research excellence.

AstraZeneca Announces Executive Changes

AstraZeneca announced the departure of its respiratory and inflammatory medicines head James Ward-Lilley to become chief executive of Vectura. His departure follows the exit earlier June 2015 of Briggs Morrison, the company's former chief medical officer and head of latestage drug development, who moved on to become CEO of Syndax.

AstraZeneca Launches Research and Development Respiratory Centre in Spain and Plans to Invest USD 613 Million in R&D to Extend Respiratory Portfolio

AstraZeneca has launched a research and development (R&D) respiratory centre in the Spanish city of Barcelona. AstraZeneca plans to invest EUR 540 million (USD 613 million) during the next three years in R&D to extend its respiratory portfolio. This new R&D centre and the future investment in it will be for developing former Almirall respiratory portfolio - mainly, the production of leading respiratory products Eklira (aclidinium) and Duaklir Genuair (aclidinium + formoterol fumarate dihydrate). Additionally, AstraZeneca plans to continue with the clinical development of some promising treatments began by Alrmirall, such as once-daily, long-acting beta2-agonist (LABA) AS100977 (abediterol) currently undergoing Phase II development, and an M3 antagonist beta2-agonist (MABA) platform - comprising LAS191351, LAS194871, in pre-clinical development, and LAS190792, in Phase I development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:LN 4,178.00 GBp +29.00

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.21 USD +0.47
BASF SE €77.41 EUR -0.51
Celgene Corp $119.28 USD +0.46
Eli Lilly & Co $88.73 USD +2.38
Valeant Pharmaceuticals International Inc C$289.22 CAD +3.01
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 64.2x
Price/Sales 3.2x
Price/Book 4.8x
Price/Cash Flow 64.1x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.